Indeed, in the CAPRAF (Candesartan in the Prevention of Relapsing Atrial Fibrillation) trial, plasma NT-proBNP concentrations measured before electrical cardioversion did not predict cardioversion success nor the relapse of AF in patients without HF [87]. Here, NPPB is linked to atrial fibrillation.